Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065116 | 1.00 | PDE10A (0.37) | PDE10AAPLNRDYRK1AAHRMAP4K4 | |
| SCHEMBL2065778 | 0.80 | AHR (0.36) | APLNRDYRK1AAHRMAP4K4PRKACA | |
| SCHEMBL2066604 | 0.80 | APLNR (0.34) | APLNRDYRK1AAHRMAP4K4PRKACA | |
| SCHEMBL2065779 | 0.80 | AHR (0.36) | APLNRDYRK1AAHRMAP4K4PRKACA | |
| SCHEMBL2066605 | 0.80 | APLNR (0.34) | APLNRDYRK1AAHRMAP4K4PRKACA | |
| SCHEMBL2066344 | 0.79 | PDE10A (0.36) | PDE10ADYRK1AAHR | |
| SCHEMBL756100 | 0.74 | KDM4E (0.50) | PDE10ADYRK1AAHR | |
| SCHEMBL3086869 | 0.73 | KDM4E (0.44) | PDE10ADYRK1AAHRLRRK2 | |
| SCHEMBL3342789 | 0.69 | PDE10A (0.39) | PDE10ADYRK1AAHR | |
| SCHEMBL2066163 | 0.69 | PDE10A (0.50) | PDE10ADYRK1AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148524-B2 | Process for producing sulfonyl chloride compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | PDE10A 3486/4885APLNR 4557/4885DYRK1A 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.